Alfresa Holdings
2784.TTSE PRIMEWholesale Trade
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥3.10T | ¥2.96T | ¥2.86T | ¥2.70T | ¥2.59T | ¥2.61T |
| Operating income | ¥36.2bn | ¥38.1bn | ¥38.5bn | ¥30.1bn | ¥29.1bn | ¥27.9bn |
| Ordinary income | ¥38.6bn | ¥40.5bn | ¥40.0bn | ¥32.8bn | ¥32.6bn | ¥31.9bn |
| Net income (owners) | ¥41.7bn | ¥27.4bn | ¥29.6bn | ¥25.8bn | ¥32.2bn | ¥24.5bn |
| Total assets | ¥1.51T | ¥1.44T | ¥1.45T | ¥1.34T | ¥1.30T | ¥1.32T |
| Net assets / equity | ¥507.9bn | ¥482.2bn | ¥479.9bn | ¥488.3bn | ¥471.8bn | ¥490.0bn |
| Operating cash flow | ¥38.6bn | ¥5.6bn | ¥86.4bn | ¥13.1bn | ¥36.5bn | −¥21.2bn |
| EPS (basic) | ¥229.64 | ¥147.54 | ¥154.13 | ¥127.42 | ¥153.57 | ¥115.75 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 201 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 69 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 201 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 69 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 201 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 47 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 71 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 45 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 201 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 47 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 71 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 45 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 201 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Dispensing Pharmacy And Related Businesses | ¥37.2bn | ¥499m |
| Ethical Pharmaceuticals Wholesaling Business | ¥2.76T | ¥33.3bn |
| Manufacturing Business | ¥37.2bn | ¥1.2bn |
| Self Medication Products Wholesaling Business | ¥266.6bn | ¥3.0bn |
| Other segments | — | −¥1.1bn |
| Adjustments & eliminations | — | −¥749m |
| Total | ¥3.10T | ¥38.0bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.